Impax receives US FDA non-approvable letter for Vadova (PharmaBiz)
Impax Laboratories, Inc., a technology based specialty pharmaceutical company, announced that it has received a non-approvable letter from the US Food and Drug Administration (FDA) concerning its new drug application for Vadova (carbidopa/levodopa) tablets.